$104.71
Value $182B
ABT and ATRC stock compared: price, dividend, valuation and results, from SEC filings.
$104.71
Value $182B
$55.02
Value $2.7B
Abbott Laboratories (ABT) has a market value of $182B and AtriCure (ATRC) $2.7B. Over the last year, with dividends, ABT moved -17.8% and ATRC +67.2%. The P/E is 38.7 for ABT and 184.1 for ATRC. Dividend yield: ABT 2.41%, ATRC none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$182B
ATRC$2.7B
ABT is 66 times ATRC
Revenue, 12 months
ABT$48.2B
ATRC$590M
ABT is 82 times ATRC
Net income, 12 months
ABT$4.7B
ATRC$15M
ABT is 316 times ATRC
Operating margin
ABT13.8%
ATRC2.9%
10.9 points apart
ROIC
ABT6.3%
ATRC2.8%
3.5 points apart
P/E
ABT38.7
ATRC184.1
ATRC is 4.8 times ABT
Dividend yield
ABT2.4%
ATRC0.0%
2.4 points apart
5-year return
ABT-11.6%
ATRC-28.2%
16.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-11.6%
ATRC-28.2%
| Period | ABTWith dividends | ATRCWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -17.8%Price -19.8% | +67.2%Price +67.2% |
| 3 years since November 17, 2023 | +12.0%+3.9% a yearPrice +5.2% | +32.6%+9.9% a yearPrice +32.6% |
| 5 years since November 16, 2021 | -11.6%-2.4% a yearPrice -20.0% | -28.2%-6.4% a yearPrice -28.2% |
| 10 years since November 17, 2016 | +212.8%+12.1% a yearPrice +159.2% | +184.9%+11.0% a yearPrice +184.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesATRCAtriCure
| Price | $104.71 | $55.02 |
|---|---|---|
| Market value | $182B | $2.7B |
| Enterprise value (EV) | $209B | $2.6B |
| P/E | 38.7 | 184.1 |
| P/E, 5-year median | 33.7 | – |
| P/B | 3.6 | 5.1 |
| EV/EBIT | 31.4 | 155.2 |
| Free cash flow yield | 3.7% | 1.9% |
| Revenue, 12 months | $48.2B | $590M |
|---|---|---|
| Net income, 12 months | $4.7B | $15M |
| Free cash flow, 12 months | $6.8B | $53M |
| Earnings per share, 12 months | $2.69 | $0.30 |
| Revenue growth, year on year | 5.7% | 14.9% |
| Revenue growth a year, past | +5.1%over 5 years | +21.0%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | – |
| Gross margin | 56.9% | 76.7% |
|---|---|---|
| Operating margin | 13.8% | 2.9% |
| Net margin | 9.8% | 2.5% |
| ROIC | 6.3% | 2.8% |
| ROE | 9.1% | 3.0% |
| Cash | $4.3B | $187M |
|---|---|---|
| Total debt | $31.2B | $97M |
| Net debt / EBITDA | 3.3 | -3.3 |
| Interest cover | 6.7× | 3.0× |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $2.52 | – |
| Dividend growth a year, past | +10.4%over 5 years | – |
| Buyback yield | 0.5% | – |
| Shareholder yield | 2.9% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($182B) is about 66.4 times AtriCure ($2.7B), at today's prices.
Since November 17, 2016, ABT's price moved +159.2% and ATRC's +184.9%. With dividends: ABT +212.8% (+12.1% a year), ATRC +184.9% (+11.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.41% for Abbott Laboratories and none for AtriCure. Over the last twelve months they paid $2.52 and – per share.
At today's price, the P/E is 38.7 for ABT and 184.1 for ATRC. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 2.5% for AtriCure, and the operating margin 13.8% and 2.9%. Revenue was $48.2B and $590M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.